TrialBMC cancer2018

Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.

Satoshi Ikeda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.